Boris Schleiffenbaum

Boris Schleiffenbaum is a notable inventor based in Brookline, MA (US). He has made significant contributions to the field of immunotherapy and antibody production. With a total of 3 patents, his work focuses on the detection and utilization of specific antibodies.

Latest Patents

Schleiffenbaum's latest patents include a method of producing a cell surface bound lam-1 specific antibody. This invention addresses the presence of a shed form of leukocyte adhesion molecule-1 (LAM-1, L-selectin) in high levels in human plasma. The patents disclose quantitative methods for detecting shed LAM-1 (sLAM-1) through Western blot and ELISA analysis. Additionally, they outline methods for the specific detection of cell-surface bound LAM-1 in the presence of shed LAM-1. His work also includes immunotherapy techniques using monoclonal antibodies that react with cell-surface bound LAM-1 but not with shed LAM-1. Furthermore, he has developed a method for producing an antibody that is reactive with cell-surface bound LAM-1 while remaining unreactive with shed LAM-1.

Career Highlights

Boris Schleiffenbaum is currently associated with the Dana-Farber Cancer Institute Inc., where he continues to advance his research and innovations. His work has been instrumental in enhancing the understanding of leukocyte adhesion molecules and their implications in cancer therapy.

Collaborations

Some of his notable coworkers include Thomas F. Tedder and Olivier Spertini. Their collaborative efforts have contributed to the advancements in the field of immunotherapy and antibody research.

Conclusion

Boris Schleiffenbaum's innovative work in the field of immunotherapy and antibody production has led to significant advancements in medical research. His contributions continue to impact the understanding and treatment of various diseases.